



Save the Date!

Clinical Research Coordinator and Site Administrator Training: All CCTC members are cordially invited to our Clinical Research Coordinator and Site Administrator Training on Tuesday May 22, 2012 at Brassaii Restaurant starting at 6 pm.

The training session will include a review the roles and responsibilities of clinical research coordinators and site administrators on the CCTC platform. Additionally, an overview of the e-referral process will be carried out using a computer demonstration.

Please RSVP to Ammar Bookwala (Email: cometrials@smh.ca, Phone: (416) 809-3915) by May 16, 2012.

Have a question, comment or concern?

Please contact Ammar Bookwala, CCTC Project Manager at CometTrials@smh.ca or call (416) 809-3915

Sponsors

Founding Sponsor



Hoffmann-La Roche Limited
At Roche, our primary objective is to provide healthcare solutions that deliver superior options for diagnosis and treatment to clinicians and patients. As one of the world's leading healthcare companies with combined strength in pharmaceuticals and diagnostics, no company is better suited for this task.

Welcome to the CCTC Monthly Newsletter!

- The COMET Clinical Trials Consortium (CCTC) is a website dedicated to improving recruitment in oncology clinical trials in the Greater Toronto Area and surrounding regions
- In our newsletter, you shall find updates about membership, featured clinical trials and news about upcoming COMET events!

Key Features of the CCTC

- Free patient referral website for medical oncologists and other cancer care specialists
- Database of actively recruiting oncology clinical trials
- Discussion Forum for best practices in cancer care
- LinkingHealthProfessionals email provided to all members to stay in touch with the COMET community
- GPS system that matches patients with the closest clinical trial site to their home address

Membership Update

The COMET Clinical Trials Consortium currently has 121 members at 18 Oncology sites. There are currently 70 active trials on the website. Please view the chart below for a detailed breakdown of members and trials per site as of April 30, 2012:

Institution	Number of Members	Number of Active Clinical Trials
Cancer Center of Southeastern Ontario	1	0
Credit Valley Hospital	13	8
Durham Regional Cancer Center	15	13
Grand River Hospital	14	6
Humber River Hospital	1	0
Markham Stouffville Hospital	1	0
North York General Hospital	7	2
Princess Margaret Hospital	14	22
Royal Victoria Hospital	7	9
Southlake Regional Health Center	8	1
St. Joseph's Healthcare Hamilton	2	0
St. Joseph's Health Center	3	2
St. Michael's Hospital	6	5
Sunnybrook/Odette Cancer Center	13	16
Toronto East General Hospital	6	2
Trillium Health Centre	5	4
Windsor Regional Hospital	2	0
York Central Hospital	3	0
Total	121	90

Please help the CCTC increase patient referrals by accessing CCTC to connect with Principal Investigators and Clinical Research Coordinators!

Trial of the Month

Name: Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Acronym: COMET-2

Primary Outcome: Confirmed pain response at Week 12 durable since Week 6 - Subjects will self-report information on pain and health-related quality of life via an interactive voice recognition system [Time Frame: Week 6 and 12]

Treatment Arms:

Arms	Assigned Interventions
<p>Experimental: Cabozantinib</p> <p>Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules.</p> <p>There will be a maximum of 10 infusions for mitoxantrone placebo.</p>	<p>Drug: Cabozantinib</p> <p>Tablets taken orally once daily.</p>
<p>Active Comparator: Mitoxantrone/Prednisone</p> <p>Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets.</p> <p>There will be a maximum of 10 infusions for mitoxantrone.</p>	<p>Drug: Mitoxantrone</p> <p>Given by IV once every 3 weeks.</p> <p>Drug: Prednisone</p> <p>Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.</p>

Study Location(s) in the Greater Toronto Area and Surrounding Regions:

Hospital	Principal Investigator	Clinical Research Coordinator
Sunnybrook Hospital	Dr. Urban Emmenegger	Ms. Nesan Bandali